Tag - RNXT

Developments

RenovoRX highlights abstract showcasing promising PK data for TAMP in LAPC

RenovoRX (NASDAQ:RNXT) has announced that an abstract presented at the ASCO Gastrointestinal Cancers Symposium 2025 highlights promising pharmacokinetic (PK) data from its patented Trans-Arterial Micro-Perfusion (TAMP)...

January 27, 2025

Developments

RenovoRx presents positive interim Phase 3 data in pancreatic cancer

RenovoRx (NASDAQ:RNXT) presented new positive data on progression-free survival from the pivotal Phase 3 open label TIGeR-PaC study of RenovoGem (intra-arterial administration of gemcitabine) in locally advanced...

June 29, 2023

Markets

Maxim starts RenovoRx at buy; PT $15

Maxim Group launched coverage of RenovoRx (NASDAQ:RNXT) with a “buy” rating and price target of $15. The stock closed at $5.72 on Oct.5. RenovoRx is developing a therapeutic platform known as, RenovoTAMP (Trans-Arterial...

October 6, 2021

Tag - RNXT

RenovoRX highlights abstract showcasing promising PK data for TAMP in LAPC

RenovoRx presents positive interim Phase 3 data in pancreatic cancer

Maxim starts RenovoRx at buy; PT $15

Subscribe